The design and synthesis of oligoamide α-helix peptidomimetics is reported. The oligoamide type systems are prepared in a modular fashion by coupling the monomers using palladium-catalyzed carbonylation chemistry. This enabled us to use substrates with a low nucleophilicity, leading to previously unreported pyrazine based oligoamide α-helix mimetics. The proof of principle is given by synthesizing a small set of compounds. Various end-capping groups were introduced and also a mixed multimer was successfully prepared.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c6ob02358d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Donor/Acceptor Ligands Based on an -Terphenyl Motif to Achieve Thermally Activated Delayed Fluorescence in Zn(II) Complexes.
Inorg Chem
January 2025
Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.
The photophysical properties of six new luminescent tetrahedral Zn(II) complexes are presented that survey two electronic donor moieties (phenolate and carbazolate) and three electronic acceptors (pyridine, pyrimidine, and pyrazine). A unique ligand based on an -terphenyl motif forms an eight-membered chelate, which enhances through-space charge-transfer (CT) interactions by limiting through-bond conjugation between the donor and acceptor. A single isomeric product was obtained in yields up to 90%.
View Article and Find Full Text PDFThe prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen.
Sci Rep
January 2025
Department of Hematology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, China.
Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. However, the relationship between the PLR and prognosis in myeloma patients has not been clearly demonstrated.
View Article and Find Full Text PDFToxicological evaluation of imidazo-based heterocyclic derivatives: and acute toxicity studies.
Toxicol Rep
June 2025
University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.
Imidazo based heterocyclic derivatives are considered as privileged scaffolds due to their presence in various pharmacologically active compounds and in marketed formulations. The present study reports toxicological evaluation of three imidazo based heterocyclic derivatives which are currently being investigated for their potential anticancer activity. Compounds IG-01-007, IG-01-008, and IG-01-009 were assessed for cytotoxicity, hemolysis, and DNA fragmentation activity.
View Article and Find Full Text PDFSimple and sensitive monitoring of polycyclic aromatic hydrocarbons in edible oils by polydimethylsiloxane/pyrazine-based hyper-crosslinked polymer coated stir bar sorptive extraction followed by gas chromatography-mass spectrometry detection.
Anal Chim Acta
February 2025
Food Laboratory of Zhongyuan, Luohe, 462000, Henan Province, PR China.
Background: Edible oils are susceptible to contamination with polycyclic aromatic hydrocarbons (PAHs) throughout production, storage, and transportation processes due to their lipophilic nature. The necessity of quantifying PAHs present in complex oil matrices at trace levels, which bind strongly to impurities in oil matrices, poses a major challenge to the accurate quantification of these contaminants. Therefore, the development of straightforward and effective methods for the separation and enrichment of PAHs in oil samples prior to instrumental analysis is paramount to guaranteeing food safety.
View Article and Find Full Text PDFProteasome Inhibitors Induce Apoptosis in Ex Vivo Cells of T-Cell Prolymphocytic Leukemia.
Int J Mol Sci
December 2024
Hematology Section, Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, 35122 Padova, Italy.
Finding an effective treatment for T-PLL patients remains a significant challenge. Alemtuzumab, currently the gold standard, is insufficient in managing the aggressiveness of the disease in the long term. Consequently, numerous efforts are underway to address this unmet clinical need.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!